The company reported an EBITDA of Rs 2,181 crore in the September quarter, higher by 13% YoY. EBITDA margins in the same period came in at 31.7%.Segment-wise, revenue from the global generics business jumped 9% year-on-year to Rs 6,110 crore, primarily driven by North America and Europe.
| Subscribe To Our Free Newsletter |
